Business
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for the Rallybio Fetal and Neonatal Alloimmune
About this update from Rallybio Corporation
[{"type":"text","content":" NEW HAVEN, Conn.--(BUSINESS WIRE)--\nRallybio Corporation (Nasdaq: RLYB) today announced that an abstract for the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study has been accepted for poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, which will be held December 9-12, 2023, in San Diego, California.\n\n\nDetails of the poster presentation are as follows:\n\n\nTitle: Identifying Pregnancies at Higher Risk for HPA-1a Alloimmunization and Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): An International, Prospective, Natural History Study\nPresenting Author: Emilie Vander Haar, M.D., Weill Cornell Medicine, New York-Presbyterian Hospital\nSession Name: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I\nDate/Time: Saturday, December 9, 2023, from 5:30 p.m. - 7:30 p.m. PT (8:30 p.m. - 10:30 p.m. ET)\nAbstract #: 1224\n\n\nThe abstract is available on the ASH Annual Meeting website. Following presentation at the meeting, the poster will be accessible via the Publications and Presentations section of Rallybio’s website www.rallybio.com.\n\n\nAbout Rallybio\n\n\nRallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.\n\n\nRallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn and Twitter.\n\n\nForward-Looking Statements\n\n\nThis press release contains forward-looking statements that are based on our management’s beliefs and assumptions and on curr...